WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205965
CAS#: 114517-02-1
Description: Fosquidone is a water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechansim of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 205965
Name: Fosquidone
CAS#: 114517-02-1
Chemical Formula: C28H22NO6P
Exact Mass: 499.11847
Molecular Weight: 499.451
Elemental Analysis: C, 67.33; H, 4.44; N, 2.80; O, 19.22; P, 6.20
Fosquidone is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: Fosquidone; GR63178A
IUPAC/Chemical Name: benzyl (14-methyl-8,13-dioxo-5,8,13,14-tetrahydrobenzo[5,6]isoindolo[2,1-b]isoquinolin-9-yl) hydrogen phosphate
InChi Key: UXTSQCOOUJTIAC-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H22NO6P/c1-17-20-11-6-5-10-19(20)14-29-15-22-25(26(17)29)27(30)21-12-7-13-23(24(21)28(22)31)35-36(32,33)34-16-18-8-3-2-4-9-18/h2-13,15,17H,14,16H2,1H3,(H,32,33)
SMILES Code: O=P(OC1=C(C2=CC=C1)C(C3=CN4CC5=C(C=CC=C5)C(C)C4=C3C2=O)=O)(OCC6=CC=CC=C6)O
The following data is based on the product molecular weight 499.451 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kaye SB, Wanders J, Clavel M, Verweij J, Piccart MJ, Smyth JF, Ten Bokkel Huinink WW, Wagener DJ, Judson IR, Cavalli F. Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. Ann Oncol. 1992 May;3(5):406-8. PubMed PMID: 1616895.
2: Planting AS, van der Burg ME, Stoter G, Beranek P, Verweij J. Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule. Clin Oncol (R Coll Radiol). 1992 May;4(3):171-3. PubMed PMID: 1586634.
3: Kaye SB, Brampton M, Harper P, Smyth J, Kerr DJ, Gore M, Green JA, Gilby E, Crawford SM, Rustin GJ. Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee. Br J Cancer. 1992 Apr;65(4):624-5. PubMed PMID: 1314072; PubMed Central PMCID: PMC1977569.